TRANSCEND CLL 004 study Published 2019-12-10 Download video MP4 360p Recommendations 02:10 Should we treat newly diagnosed patients with CLL differently after ASH 2019? 03:24 Dr. Jeffrey Weitzel on Synthetic Lethality in BRCA-Associated Cancer 01:38 Dr. Lee on Differences Between HIPEC and PIPAC in mCRC 05:37 What is the role of treatment line and duration in patients with LBCL treated with CAR T cells? 25:40 I have lost my hearing (bilateral profound SSNHL)[CC] 38:36 Atrial Fibrillation: New Solutions for an Old Problem 18:40 Matthew Perry's Death From Ketamine Explained (Is It Safe For You?) 1:02:48 The Final Episode of CHEF AJ LIVE! Q & A with NYT Bestselling Author Dr. Joel Fuhrman - Episode 2078 01:36 Meet Hematologist Alex F. Herrera, M.D. | City of Hope 31:44 Sarcopenic Obesity with Dr. Ben Bikman 01:05 Effect of cabozantinib on quality of life in renal cell carcinoma 04:31 Understanding Parkinson's disease 07:22 Stem Cell Transplantation in Patients with MDS 25:58 Interview With A Stage 4 Lung Cancer Survivor (Jill Hamer-Wilson) 09:16 What are the take-home messages from 17-ICML? 06:27 Prostaglandin Analogs, Cholinergic Receptors Agonists, Fixed Combination Agents 59:58 Recovery from AVM (Arteriovenous Malformation) Stroke | Jason Gaudette EP 56 05:34 Soft Tissue Sarcoma: Factors Impacting Initial Approach 34:08 My Chronic Lyme Disease Journey PT. 3 | Symptoms | Antibiotics | Breaking Point | Recovery 07:46 Practical Experience with Iron Chelating Agents Similar videos 04:00 The TRANSCEND-CLL-004 study: JCAR017 03:17 TRANSCEND-CLL-004 study update: safety and efficacy of liso-cel in R/R CLL 07:52 Dr. Siddiqi on Liso-Cel in the TRANSCEND CLL 004 Study 01:12 Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL 03:56 TRANSCEND-CLL-004: liso-cel in CLL 04:26 TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL 03:09 Liso-cel induces rapid uMRD: TRANSCEND-CLL-004 update 03:34 TRANSCEND-CLL-004: pivotal in the FDA approval of liso-cel for R/R CLL 04:20 Extended follow-up of the TRANSCEND-CLL-004 monotherapy cohort 01:29 TRANSCEND-CLL-04: 18-month follow-up of liso-cel for R/R CLL 01:14 Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL 01:07 The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial 02:32 MRD status after liso-cel in the TRANSCEND-CLL-004 trial 03:12 Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004 11:44 TRANSCEND CLL004: Might CAR T-cell therapy become standard-of-care for CLL? 06:19 Lisocabtagene maraleucel is efficacious at treating R/R CLL/SLL 03:53 Latest updates on liso-cel for R/R CLL/SLL 01:49 CAR-T cell approaches in CLL: current progress & future directions 01:17 Preliminary results from Phase I trial of liso-cel plus ibrutinib for R/R CLL More results